Antidiabetic effects of corni fructus extract in streptozotocin-induced diabetic rats

Yonsei Medical Journal

Volumn 53, Issue 4, 2012, Pages 691-700

  Gao, Dawei ^a   Li, Qingwang ^a   Gao, Zhengrong ^b   Wang, Lixin ^a  

^a YANSHAN UNIVERSITY   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Antioxidant enzymes; Corni Fructus (Cornus officinalis Sieb. et Zucc.); Diabetic nephropathy; Peroxisome proliferator activated receptor (PPAR )

Indexed keywords

ANTIDIABETIC AGENT; CATALASE; CORNI FRUCTUS EXTRACT; CREATININE; GLUCOSE; GLUTATHIONE PEROXIDASE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLANT EXTRACT; SERUM ALBUMIN; STREPTOZOCIN; SUPEROXIDE DISMUTASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORNI FRUCTUS; CORNUS; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; ENZYME ACTIVITY; FLUID INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; IN VIVO STUDY; KIDNEY FUNCTION; KIDNEY HYPERTROPHY; MALE; NONHUMAN; ORAL GLUCOSE TOLERANCE TEST; OXIDATIVE STRESS; PROTEIN EXPRESSION; PROTEIN URINE LEVEL; RAT; STREPTOZOCIN DIABETES; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CATALASE; CORNUS; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; GLUTATHIONE; HYPOGLYCEMIC AGENTS; MALE; MALONDIALDEHYDE; PLANT EXTRACTS; RATS; RATS, WISTAR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SUPEROXIDE DISMUTASE;

EID: 84863111471     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2012.53.4.691     Document Type: Article

References (41)

1. Cooper ME, Allen TJ, O'Brien RC, Macmillan PA, Clarke B, Jerums G, et al. Effects of genetic hypertension on diabetic nephropathy in the rat--functional and structural characteristics. J Hypertens 1988;6:1009-16.
2. Prabhakar S, Starnes J, Shi S, Lonis B, Tran R. Diabetic nephropathy is associated with oxidative stress and decreased renal nitric oxide production. J Am Soc Nephrol 2007;18:2945-52.
3. Ceriello A, Bortolotti N, Falleti E, Taboga C, Tonutti L, Crescentini A, et al. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 1997;20:194-7.
4. Yang HC, Ma LJ, Ma J, Fogo AB. Peroxisome proliferator-activated receptor-gamma agonist is protective in podocyte injury-associated sclerosis. Kidney Int 2006;69:1756-64.
5. Pascual G, Fong AL, Ogawa S, Gamliel A, Li AC, Perissi V, et al. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma. Nature 2005;437: 759-63.
6. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B. Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 2007;1771:1065-81.
7. Kuroe A, Taniuguchi A, Fukushima M, Nakai Y, Ohgushi M, Ohya M, et al. Early and late onset side effects of short-acting insulin analogue in seven Japanese diabetic patients. Diabetes Res Clin Pract 2007;77:412-3.
8. Shoji Y, Nakashima H. Glucose-lowering effect of powder formulation of African black tea extract in KK-A(y)/TaJcl diabetic mouse. Arch Pharm Res 2006;29:786-94.
9. Kochhar A, Nagi M. Effect of supplementation of traditional medicinal plants on blood glucose in non-insulin-dependent diabetics: a pilot study. J Med Food 2005;8:545-9.
10. Qian DS, Zhu YF, Zhu Q. [Effect of alcohol extract of Cornus officinalis Sieb. et Zucc on GLUT4 expression in skeletal muscle in type 2 (non-insulin-dependent) diabetic mellitus rats]. Zhongguo Zhong Yao Za Zhi 2001;26:859-62.
11. Wu VC, Qiu X, Peggy Hsieh YH. Evaluation of Escherichia coli O157:H7 in apple juice with Cornus fruit (Cornus officinalis Sieb. et Zucc.) extract by conventional media and thin agar layer method. Food Microbiol 2008;25:190-5.
12. Peng Q, Wei Z, Lau BH. Fructus corni attenuates oxidative stress in macrophages and endothelial cells. Am J Chin Med 1998;26: 291-300.
13. Gao D, Li N, Li Q, Li J, Han Z, Fan Y, et al. Study of the extraction, purification and antidiabetic potential of ursolic acid from Cornus officinalis Sieb. et Zucc. Therapy 2008;5:697-705.
14. Gao D, Li Q, Li Y, Liu Z, Liu Z, Fan Y, et al. Antidiabetic potential of oleanolic acid from Ligustrum lucidum Ait. Can J Physiol Pharmacol 2007;85:1076-83.
15. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969;22:158-61.
16. Asami-Miyagishi R, Iseki S, Usui M, Uchida K, Kubo H, Morita I. Expression and function of PPARgamma in rat placental development. Biochem Biophys Res Commun 2004;315:497-501.
17. van Bamme B, Koudstaal J. Measuring glomerular diameters in tissue sections. Virchows Arch A Pathol Anat Histol 1976;369: 283-91.
18. Liu IM, Tzeng TF, Liou SS, Chang CJ. The amelioration of streptozotocin diabetes-induced renal damage by Wu-Ling-San (Hoelen Five Herb Formula), a traditional Chinese prescription. J Ethnopharmacol 2009;124:211-8.
19. Shapiro K, Gong WC. Natural products used for diabetes. J Am Pharm Assoc (Wash) 2002;42:217-26.
20. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res 2006;3:147-58.
21. Ozsoy-Sacan O, Karabulut-Bulan O, Bolkent S, Yanardag R, Ozgey Y. Effects of chard (Beta vulgaris L. var cicla) on the liver of the diabetic rats: a morphological and biochemical study. Biosci Biotechnol Biochem 2004;68:1640-8.
22. WHO Expert Committee on Diabetes Mellitus: Second Report. Geneva, Switzerland: World Health Organization; 1980. Technical report series 646. 18.
23. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
24. Ahn CW, Song YD, Kim JH, Lim SK, Choi KH, Kim KR, et al. The validity of random urine specimen albumin measurement as a screening test for diabetic nephropathy. Yonsei Med J 1999;40:40-5.
25. Falk RJ, Scheinman JI, Mauer SM, Michael AF. Polyantigenic expansion of basement membrane constituents in diabetic nephropathy. Diabetes 1983;32 Suppl 2:34-9.
26. Soria B, Roche E, Berná G, León-Quinto T, Reig JA, Martín F. Insulin-secreting cells derived from embryonic stem cells normalize glycemia in streptozotocin-induced diabetic mice. Diabetes 2000;49:157-62.
27. Chen V, Ianuzzo CD. Dosage effect of streptozotocin on rat tissue enzyme activities and glycogen concentration. Can J Physiol Pharmacol 1982;60:1251-6.
28. Rabinovitch A, Suarez WL, Thomas PD, Strynadka K, Simpson I. Cytotoxic effects of cytokines on rat islets: evidence for involvement of free radicals and lipid peroxidation. Diabetologia 1992;35: 409-13.
29. Reddy SV, Tiwari AK, Kumar US, Rao RJ, Rao JM. Free radical scavenging, enzyme inhibitory constituents from antidiabetic Ayurvedic medicinal plant Hydnocarpus wightiana Blume. Phytother Res 2005;19:277-81.
30. Hunt JV, Smith CC, Wolff SP. Autoxidative glycosylation and possible involvement of peroxides and free radicals in LDL modification by glucose. Diabetes 1990;39:1420-4.
31. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J. Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 2000;26:163-76.
32. Zheng F, Fornoni A, Elliot SJ, Guan Y, Breyer MD, Striker LJ, et al. Upregulation of type I collagen by TGF-beta in mesangial cells is blocked by PPARgamma activation. Am J Physiol Renal Physiol 2002;282:F639-48.
33. Berger J, Moller DE. The mechanisms of action of PPARs. Annu Rev Med 2002;53:409-35.
34. Hamm JK, el Jack AK, Pilch PF, Farmer SR. Role of PPAR gamma in regulating adipocyte differentiation and insulin-responsive glucose uptake. Ann N Y Acad Sci 1999;892:134-45.
35. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-56.
36. Iwata M, Haruta T, Usui I, Takata Y, Takano A, Uno T, et al. Pioglitazone ameliorates tumor necrosis factor-alpha-induced insulin resistance by a mechanism independent of adipogenic activity of peroxisome proliferator--activated receptor-gamma. Diabetes 2001;50:1083-92.
37. Li D, Wang X, Ren W, Ren J, Lan X, Wang F, et al. High expression of liver histone deacetylase 3 contributes to high-fat-diet-induced metabolic syndrome by suppressing the PPAR-γ and LXR-α-pathways in E3 rats. Mol Cell Endocrinol 2011;344:69-80.
38. Zhang H, Saha J, Byun J, Schin M, Lorenz M, Kennedy RT, et al. Rosiglitazone reduces renal and plasma markers of oxidative injury and reverses urinary metabolite abnormalities in the amelioration of diabetic nephropathy. Am J Physiol Renal Physiol 2008; 295:F1071-81.
39. Rose M, Balakumar P, Singh M. Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. Pharmacology 2007;80:177-84.
40. Lee KS, Kim SR, Park SJ, Park HS, Min KH, Jin SM, et al. Peroxisome proliferator activated receptor-gamma modulates reactive oxygen species generation and activation of nuclear factor-kappaB and hypoxia-inducible factor 1alpha in allergic airway disease of mice. J Allergy Clin Immunol 2006;118:120-7.
41. Buckingham RE, Al-Barazanji KA, Toseland CD, Slaughter M, Connor SC, West A, et al. Peroxisome proliferator-activated receptor-gamma agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes 1998;47:1326-34.